Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 8/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | LY96 | Q9Y6Y9 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16864091 | 1.00 | TLR4 (0.35) | TLR4L3MBTL1LMNAKMT2AABCB1 | |
| SCHEMBL15928020 | 1.00 | TLR4 (0.35) | TLR4L3MBTL1LMNAKMT2AABCB1 | |
| SCHEMBL2336438 | 1.00 | TLR4 (0.35) | TLR4L3MBTL1LMNAKMT2AABCB1 | |
| SCHEMBL7155167 | 0.84 | LMNA (0.35) | L3MBTL1LMNAKMT2ACA1CA2 | |
| SCHEMBL7566969 | 0.81 | KMT2A (0.37) | KMT2ACA1CA2CA9 | |
| SCHEMBL7566809 | 0.81 | L3MBTL1 (0.34) | L3MBTL1 | |
| SCHEMBL2802558 | 0.75 | — | — | |
| SCHEMBL12560770 | 0.74 | MAPK1 (0.40) | L3MBTL1KMT2ACA1CA2 | |
| SCHEMBL10204186 | 0.73 | CA2 (0.57) | LMNAKMT2AABCB1CA1CA2 | |
| SCHEMBL14541656 | 0.72 | MAPK1 (0.37) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140220630-A1 | HYBRID SCFA-HYDROXYL-DERIVATIZED MONOSACCHARIDES, METHODS OF SYNTHESIS, AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140220630-A1 | HYBRID SCFA-HYDROXYL-DERIVATIZED MONOSACCHARIDES, METHODS OF SYNTHESIS, AND METHODS OF TREATING DISORDERS | HCAR2, HSD17B14, FASN | TLR4 704/4885L3MBTL1 2779/4885LMNA 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.